Results 101 to 110 of about 3,103 (172)

Off-label treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: real-world evidence from the German CF Registry. [PDF]

open access: yesERJ Open Res
Stahl M   +5 more
europepmc   +1 more source

Effect of elexacaftor–tezacaftor–ivacaftor modulator on lung structure in cystic fibrosis

open access: yesPulmonology, 2023
V. Fainardi   +5 more
doaj   +1 more source

Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence. [PDF]

open access: yesJ Clin Med
Boni A   +11 more
europepmc   +1 more source

Elexacaftor, Tezacaftor, and Ivacaftor

open access: yesAmerican Journal of Health-System Pharmacy, 2020
openaire   +1 more source

Long-Term Adherence to Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis. [PDF]

open access: yesPulm Ther
Hansen CME   +4 more
europepmc   +1 more source

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]

open access: yesJ Patient Rep Outcomes
Buniotto F   +6 more
europepmc   +1 more source

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103) : results from two randomised, active-controlled, phase 3 trials

open access: yes
BackgroundThe goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis.
Fabrizzi, Benedetta   +240 more
core  

Home - About - Disclaimer - Privacy